AI in Healthcare
The latest on artificial intelligence transforming medicine
News stories discovered and organized by an automated pipeline. Covering clinical deployments, research breakthroughs, regulation, and industry developments.
Incyte-Genesis Expands AI Drug Discovery Pact With $120M Funding and New Targets
Incyte and Genesis are deepening their AI drug discovery collaboration with $120 million in funding and additional targets. The expanded deal shows how pharma-AI partnerships are increasingly being structured as long-term discovery programs rather than short-term experiments.
Incyte and Genesis Expand Their AI Drug Discovery Pact Above $1 Billion
Incyte and Genesis have expanded their AI collaboration into a deal valued at more than $1 billion, another sign that biotech is willing to pay for computational discovery platforms. The agreement adds to a growing list of large partnerships betting that AI can improve pipeline quality.
Lilly, BMS, and Incyte Keep the AI Drug Discovery Deal Cycle Moving
A string of new deals from Lilly, Bristol Myers Squibb, and Incyte shows that AI integration is becoming a sustained biopharma trend rather than a one-off experiment. The question now is whether these deals will produce better drugs, or simply more collaboration headlines.
Inside Incyte’s $120 Million AI Drug Development Deal
Forbes reports that Incyte’s latest AI-for-drug-development agreement is worth $120 million, highlighting how quickly these collaborations are growing in size and ambition. The deal reflects a market where pharma is increasingly willing to pay for access to AI-driven discovery capacity.
Incyte’s AI Push Grows Into a Bigger Bet on Discovery Infrastructure
Incyte has deepened its AI strategy with new partnerships involving Edison Scientific and Genesis, including a reported $80 million expansion to its collaboration with Genesis. Together, the deals show how biopharma is moving from one-off AI experiments toward embedded discovery infrastructure.
Incyte Deepens Its AI Drug Discovery Bet With a New $120M Boost
Incyte’s expanded AI drug discovery agreement signals that big pharma is still willing to pay up for faster target identification and better early-stage pipelines. The deal highlights how AI partnerships are evolving from experimental side projects into core R&D strategy.
Incyte Deepens Its AI Bet With Edison Scientific and Genesis, Turning Discovery Into an Infrastructure Play
Incyte announced two related AI collaborations in quick succession, pairing with Edison Scientific on an integrated discovery-and-translation platform and with Genesis on a molecular AI effort backed by new funding and targets. The moves suggest the company is no longer treating AI as a side experiment, but as core infrastructure for how it will generate and prioritize drug programs. That matters because the next phase of AI in pharma is less about flashy model demos and more about whether these systems can actually shrink the cycle time between hypothesis, target selection and translational decision-making.
Incyte and Edison Scientific Put AI on the Critical Path for Drug Research
Incyte’s partnership with Edison Scientific adds another signal that pharma companies are trying to move AI from point solutions into the center of discovery operations. The collaboration focuses on an AI platform for drug research, reflecting a growing industry belief that workflow integration matters as much as model performance. The key question is whether these platforms can reduce decision friction in real research settings, where data quality, experimental noise and organizational inertia often matter more than algorithmic sophistication.
Incyte and Edison Deal Highlights a New Market for Training AI on Drug Discovery Work
Incyte’s agreement with Edison is part of a broader trend toward using active drug discovery programs as training ground for AI systems. Rather than treating AI as a standalone product, companies are increasingly trying to make discovery itself into a continuous data engine.
How this works
Discover
An automated pipeline searches the web for significant AI healthcare news across clinical, research, regulatory, and industry domains.
Structure
The pipeline turns source material into concise, readable stories with categories, tags, and context that make the feed easier to scan.
Publish
Stories are deduplicated, stored, and published to this site. The pipeline runs automatically to keep coverage current.